Research Protocol for Psilocybin Pilot Trial in Late-Life Depression

A comprehensive plan for evaluating a 25 mg psilocybin treatment in inpatient settings

Highlights

Feasibility and Implementation: Evaluate if psilocybin administration can be smoothly integrated into inpatient clinical routines through structured preparatory, dosing, and integration procedures.
Safety Profile: Monitor vital signs, adverse events, and psychiatric safety using continuous and multidisciplinary oversight to ensure participant well-being.
Efficacy Assessment: Use standardized depression scales (e.g., MADRS, HDRS) to measure the therapeutic impact while gathering preliminary data to inform future controlled studies.

Introduction and Rationale

Late-life depression is a significant challenge in contemporary mental health management, particularly given the complexity of treatment-resistant depression in older adults. Traditional antidepressant treatments often fall short in remediating depressive symptoms in this age group, exacerbated by comorbid medical conditions and issues of polypharmacy. Over the past few years, emerging evidence has indicated that psilocybin, a naturally occurring psychedelic compound, may offer rapid and sustained antidepressant effects.

The proposed study is an open-label, one-arm pilot trial designed to evaluate the feasibility, as well as the safety and preliminary efficacy, of a single 25 mg dose of psilocybin in an inpatient setting for late-life depression. By testing the implementation of this innovative treatment approach within the controlled environment of a psychiatric inpatient unit, the study aims to determine whether psilocybin-assisted therapy can be reliably integrated into current clinical routines and pave the way for future, more extensive randomized controlled trials.

Study Objectives

Primary Objective

The primary objective is to assess the feasibility of administering a single 25 mg dose of psilocybin in an inpatient setting among elderly patients with major depressive disorder. Feasibility will be evaluated based on:

Recruitment and enrollment rates.
Adherence to protocol procedures including preparatory sessions, dosing, and follow-up assessments.
Integration of psilocybin therapy into existing clinical routines and inpatient workflows.

Secondary Objectives

Secondary objectives are designed to evaluate the safety and preliminary efficacy of the intervention:

Assessing the safety profile through continuous monitoring of vital signs, adverse events, laboratory and ECG assessments, and close clinical supervision during and after the psilocybin dosing session.
Measuring changes in depressive symptoms using standardized rating scales, including the Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HDRS).
Evaluating the acceptability and implementation challenges from the perspective of both clinical staff and patients using structured feedback surveys.

Study Design and Methodology

Type of Study

The study is designed as an open-label, single-arm pilot trial. This design involves administering a single dose of 25 mg psilocybin to all enrolled participants without the use of placebo or a comparator group. This structure is aimed at primarily gauging feasibility and safety rather than conducting a full efficacy trial.

Setting

The trial will be conducted in an inpatient psychiatric unit that specializes in the treatment of late-life depression. The inpatient setting provides a controlled environment enabling intensive monitoring, immediate access to emergency care if needed, and a supportive atmosphere conducive to careful therapeutic intervention.

Trial Duration

The overall duration is planned for 12 weeks which includes an 8-week period of treatment and an additional 4-week follow-up. Detailed timelines include pre-dosing assessments, the dosing day with intensive observation, early post-intervention monitoring, and subsequent follow-up assessments to capture both immediate and sustained effects.

Sample Size

Given its pilot nature, the study will aim to enroll approximately 20-30 participants. This range is considered sufficient to provide a robust set of feasibility and safety metrics while limiting exposure to risk in this exploratory phase.

Participant Selection and Criteria

Inclusion Criteria

The inclusion criteria will include:

Age: Participants must be 65 years or older.
Diagnosis: A confirmed diagnosis of major depressive disorder (MDD) according to DSM-5 criteria, with particular attention to cases defined as treatment-resistant.
Inpatient Status: Patients must currently be engaged in inpatient psychiatric treatment.
Capacity: Ability to provide informed consent, as validated by a cognitive screening procedure ensuring sufficient understanding of the study and its procedures.
Stabilization: Participants should be stable on any concomitant medications for a minimum of 4 weeks prior to enrollment.

Exclusion Criteria

Exclusion criteria consist of:

History of psychotic disorders, bipolar disorder, or current psychosis, making them unsuitable for psychedelic intervention.
Substance Abuse: Current substance misuse or dependence that may interfere with the study’s safety or outcomes.
Medical Contraindications: Any uncontrolled or severe medical conditions, particularly cardiovascular illnesses, that could be exacerbated by psilocybin.
Medication Interference: Use of medications known to significantly interfere with psilocybin’s pharmacodynamic profile, unless adjustments can be made safely under medical supervision.
Suicidality: High risk for suicide or inability to comply with intensive follow-up monitoring.
Other: Any contraindications identified during comprehensive pre-screening evaluations.

Intervention and Procedures

Overview of the Intervention

The central intervention of this trial is a single oral dose of 25 mg psilocybin. Administration of the drug will take place in a controlled, therapeutically supportive setting designed specifically for the purpose of psilocybin dosing and integration.

Pre-administration Procedures

Prior to psilocybin administration, each participant will undergo a thorough screening and baseline assessment. These include:

Medical examination including ECG and laboratory tests to ensure eligibility and safety.
Psychiatric evaluation using standardized instruments such as the MADRS and HDRS to document baseline depressive symptoms.
Preparatory psychotherapy sessions conducted by trained clinicians to prepare participants for the potential psychological experiences during dosing and set appropriate expectations.

Dosing Day Procedures

On the dosing day:

Participants will be escorted to a dedicated treatment room designed to be both comforting and safe.
A trained multidisciplinary team, including a psychiatrist and nursing staff, will supervise the session. Continuous monitoring of vital signs and psychological status will be implemented throughout the acute phase of the drug’s effect.
Emergency protocols will be in place, with immediate access to rescue medications such as benzodiazepines to manage anxiety or other acute reactions if needed.

Post-administration and Follow-Up

Post-dosing, all participants will be closely monitored during an integration phase:

An integration session will be scheduled within 24 hours after dosing. This session helps participants process their experiences and consolidate any psychological insights gained during the session.
Daily observational assessments will be conducted during the first week to monitor immediate reactions and side effects.
Follow-up assessments are scheduled at weeks 1, 2, 4, 8, and 12 after psilocybin administration, wherein clinical staff will administer standardized psychometric scales for depression and monitor any adverse events.

Outcome Measures and Data Collection

Primary Outcomes

Primary outcomes focus on the feasibility of the treatment protocol:

Feasibility Metrics: These include recruitment success, retention rates, protocol adherence, and integration into clinical routines as measured by standardized staff and patient surveys.
Safety Evaluations: Monitoring adverse events, changes in vital signs, laboratory results, and any ECG abnormalities recorded throughout the study duration.

Secondary Outcomes

Secondary outcomes are designed to gauge the preliminary efficacy and additional health outcomes:

Efficacy: Changes in depression scores as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HDRS) pre- and post-treatment.
Quality of Life and Cognitive Measures: Evaluations utilizing ancillary scales that assess quality of life and cognitive function, providing a holistic view of the intervention’s impact.
Implementation Feedback: Structured questionnaires and qualitative interviews with staff and participants to assess acceptability and practical implementation challenges.

Data Collection and Analysis

Data will be collected through an electronic case report form (eCRF) system, ensuring accurate and secure documentation. All data acquisition processes will adhere to EU General Data Protection Regulation (GDPR) guidelines.

The statistical analysis plan is structured as follows:

Descriptive and Inferential Statistics

Descriptive statistics will summarize patient demographics, feasibility measures, and safety outcomes using means, standard deviations, and frequencies. Paired t-tests (or non-parametric equivalents) will assess changes in depression scores from baseline to all follow-up time points. Confidence intervals (95%) will be used to interpret the precision of the estimates.

Handling of Missing Data

Any missing data will be documented and sensitivity analyses performed if dropout rates exceed acceptable limits. An intention-to-treat approach will be used to analyze efficacy data, ensuring that all enrolled participants are included in the statistical analyses.

Data Safety Monitoring

A Data Safety Monitoring Board (DSMB) composed of independent experts will periodically review the safety and integrity of the trial data. Pre-defined stopping rules will include:

Issuance of any serious adverse event (SAE) related to psilocybin administration that raises safety concerns.
Evidence of significant clinical harm or unexpected safety signals identified in the participant pool.

Safety Reporting Procedures

Any adverse events will be immediately recorded and reported to the sponsor and ethics committee in compliance with EU CTIS requirements. An interim safety analysis is planned after the first 10 participants complete their 2-week follow-up visit.

Ethical Considerations and Regulatory Compliance

Informed Consent and Autonomy

Ensuring voluntary, informed consent is paramount. All participants will be provided with a detailed explanation of the study objectives, potential risks, and benefits in accordance with the Declaration of Helsinki and ICH-GCP guidelines. Particular emphasis will be placed on ensuring that participants fully comprehend the nature of a one-arm, open-label trial.

Ethics Committee Approval

The study protocol, including all supporting documents such as the informed consent form, will be submitted for ethics committee review and approval. All modifications to the protocol will be subject to further ethical review.

Regulatory Compliance

The trial is specifically designed to comply with the Clinical Trials Regulation (EU) 536/2014 and will be registered with the EU Clinical Trials Information System (CTIS). All trial registrations and documentation will adhere to the strict requirements of EU regulatory bodies, ensuring proper oversight and transparency.

Operational Plan and Timeline

The following table outlines the key phases of the study, associated procedures, and timelines:

Phase	Timeline	Key Procedures
Screening Phase	Days -14 to -1	Informed Consent Medical Evaluation Baseline Psychometric Assessments (MADRS, HDRS) ECG and Laboratory Tests
Baseline Assessment and Preparation	Day 0	Preparatory Psychotherapy Session Final Review of Inclusion/Exclusion Criteria
Intervention (Dosing Day)	Day 1	Administration of 25 mg Psilocybin Continuous Clinical and Psychological Monitoring Acute Phase Support and Emergent Interventions
Post-Dosing Observation	Days 1-7	Daily Safety and Psychological Assessments Integration Session within 24 Hours
Follow-Up Assessments	Weeks 1, 2, 4, 8, and 12	Repeat Psychometric Evaluations (MADRS, HDRS, etc.) Monitoring Adverse Events Clinical Staff and Patient Feedback Collection

Quality Control and Data Management

Quality Assurance Measures

To ensure the integrity of the study data, all trial processes will be subject to rigorous quality control measures:

Regular monitoring visits will be conducted to verify adherence to the protocol.
All data will be recorded in an electronic Case Report Form (eCRF) featuring built-in audit trails.
Training sessions will be organized for clinical and research staff to ensure consistency and high standards in data collection and patient care.

Data Management

Data will be managed in strict compliance with EU GDPR regulations. A comprehensive data management plan will be implemented to:

Ensure secure storage and handling of sensitive patient information.
Outline clear procedures for data entry, backup, and quality control checks.
Establish guidelines for the eventual anonymization and destruction of trial data.

Conclusion and Final Thoughts

This research protocol outlines a comprehensive plan for an open-label, single-arm pilot trial to evaluate the feasibility, safety, and initial efficacy of a 25 mg dose of psilocybin in the treatment of late-life depression within an inpatient setting. The design of the trial is constructed to satisfy the rigid requirements of the EU Clinical Trials Information System (CTIS) with a particular emphasis on enabling integration into clinical practice.

The key strengths of this protocol include its rigorous patient screening and consent process, the controlled administration environment that ensures patient safety, and the detailed schedule for pre-dosing preparation and post-dosing integration therapy. Standardized outcome measures such as MADRS and HDRS will provide initial efficacy data and support further development into larger, randomized controlled trials.

By addressing both the practical and clinical challenges of implementing novel treatment approaches in geriatric psychiatry, this study has the potential to contribute significantly to the evolving field of psychedelic-assisted therapy. Future studies will benefit from the insights gained in recruitment efficiency, protocol adherence, and the overall acceptability of the psilocybin treatment approach in a specialized inpatient setting.